Business

TScan Therapeutics announces ~$30M direct offering (NASDAQ:TCRX)

Avatar of Ui9Posted by


  • Biotechnology company TScan Therapeutics (NASDAQ:TCRX) announced on Thursday the sale of ~$30M of pre-funded warrants to purchase up to an aggregate of 7.5M voting shares at $4.00 per pre-funded warrant.
  • TCRX has entered into a securities purchase agreement with Lynx1


Rate this post

Leave a Reply

Email của bạn sẽ không được hiển thị công khai. Các trường bắt buộc được đánh dấu *